id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-259691-3bo4md44	Zhao, Ming	Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies	2020-04-16		.txt	text/plain	1236	70	39	• Other immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19. Combined use of an immunomodulatory agentto reduce the cytokine stormwith an antiviral agent may give physicians more time to provide supportive treatment for patients with Corticosteroids are among the most commonly used drugs for immunomodulatory therapy of infectious diseases. Tocilizumab, a specific monoclonal antibody that blocks IL-6, has been recommended for use in severe or critically ill patients with extensive lesions in bilateral lungs and a confirmed elevated level of IL-6 in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) issued by the National Health Commission of China [7] . Overall, certain immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19.	./cache/cord-259691-3bo4md44.txt	./txt/cord-259691-3bo4md44.txt